– Approval Based on Phase 3 PURPOSE 1 and PURPOSE 2 Data that Showed ≥99.9% of Participants Remained HIV Negative on Twice-Yearly Injectable Yeztugo – – Yeztugo, Nearly 20 Years in the Making, ...

– New Data from PURPOSE Trials Further Demonstrate that Lenacapavir (Yeztugo ®) was Effective and Well Tolerated Across a Broad Range of Populations, Including Pregnant and Lactating Women, ...

Gilead’s recently approved drug for HIV prevention, Yeztugo (lenacapavir), has the potential to transform the pre-exposure prophylaxis (PrEP) sector in the US, according to market analysts. The US ...

Gilead Sciences, Inc. (NASDAQ:GILD) on Wednesday announced a strategic partnership agreement with the Global Fund to Fight AIDS, Tuberculosis and Malaria to supply lenacapavir — Gilead’s twice-yearly ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced a strategic partnership agreement with the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund) ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced it has been awarded the prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product for Yeztugo® (lenacapavir), the company’s ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization for Yeytuo® (lenacapavir)—the company’s twice-yearly injectable HIV-1 capsid ...

The fight to end HIV in our lifetimes just received a game-changing innovation. In June, the FDA approved Yeztugo (lenacapavir), a groundbreaking HIV prevention treatment that requires just two ...

CVS Health Inc. (NYSE:CVS) said it will not add Gilead Sciences Inc.’s (NASDAQ:GILD) new HIV prevention drug Yeztugo to its commercial plans. In June, the U.S. Food and Drug Administration (FDA) ...

CVS Health, one of the nation’s largest pharmacy benefit managers, has declined to cover Gilead’s newly FDA-approved HIV prevention drug Yeztugo (lenacapavir), a twice-yearly injection shown to be ...

– Gilead’s Research Presentations and Community Events at IAS Reflect Commitment to Partnerships in Developing Person-Centered Options for a Diverse Range of Populations – FOSTER CITY, ...

(RTTNews) - Gilead Sciences, Inc. (GILD) Monday announced that Gilead researchers and collaborators will present new Phase 3 Purpose trial data at IAS 2025 showing that twice-yearly lenacapavir ...